Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) will report its second quarter 2021 financial results on August 5, 2021. A conference call hosted by the management team is scheduled for 8:30 a.m. ET on the same day to discuss the results and provide company updates. Karyopharm specializes in developing novel cancer therapies, focusing on SINE compounds that inhibit the nuclear export protein XPO1, with its lead product XPOVIO already approved in the U.S. for various malignancies.

Positive

• Karyopharm's lead compound, XPOVIO, is already approved in multiple hematologic malignancies.
• The company is dedicated to pioneering novel cancer therapies, indicating growth potential and expanding pipeline.

Negative

• None.

NEWTON, Mass., July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, August 5, 2021, to discuss the financial results and other company updates.

To access the conference call, please dial (888) 437-3179 (local) or (862) 298-0702 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. NEXPOVIO® (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

View original content:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2021-financial-results-on-august-5-2021-301343871.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm Therapeutics report its second quarter 2021 financial results?

Karyopharm will report its second quarter 2021 financial results on August 5, 2021.

What time is the Karyopharm conference call on August 5, 2021?

The conference call is scheduled for 8:30 a.m. ET on August 5, 2021.

What is Karyopharm Therapeutics' lead product and its approval status?

Karyopharm's lead product is XPOVIO, which is approved in the U.S. for multiple hematologic malignancies.

Where can I access the Karyopharm conference call?

The conference call can be accessed by dialing (888) 437-3179 locally or (862) 298-0702 internationally, or by visiting their Investor section for a live audio webcast.